Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients (NCT02359123) | Clinical Trial Compass
CompletedNot Applicable
Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients
Israel24 participantsStarted 2016-11
Plain-language summary
The main purpose in the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS) is to prolong life and to improve quality of life (QoL) as far as possible. QoL in patients with CACS is directly related to loss of appetite and loss of weight. Cannabis pills are given in Israel to advanced cancer patients with various symptoms in order to improve their QoL. There is data on safety/toxicity of cannabis, and these pills are given under the regulations of the Israel Ministry of Health.
The purpose of this study is to examine the influence of Cannabics capsules on improving loss of appetite and loss of weight.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age above 18 years
✓. Histological evidence of an incurable malignancy
✓. Estimated life expectancy ≥3 months
✓. Performance status ≤2 (ECOG classification)
✓. Self-report of weight loss of at least 3kg during the preceding 2 months and/or a dietitian-estimated caloric intake of less than 20 calories/kg of body weight per day
✓. Patient believes that loss of appetite or loss of weight is an ongoing problem for him
✓. Use of chemotherapy or radiotherapy is permitted
✓. Sign of written informed consent
Exclusion criteria
✕. Ongoing use of tube feedings or parental nutrition
✕. Edema or ascites
✕
What they're measuring
1
weight gain of ≥10% from baseline weight assessed.
. Central nervous system metastases or brain tumors (patients with stable disease in the brain 28 days after treatment can be included in the study)
✕. Treatment with adrenal corticosteroids (except for short-term dexamethasone during time of chemotherapy), androgens, progestational agents or other appetite stimulants within the previous two weeks
✕. Insulin-requiring diabetes
✕. Pregnancy or lactation or unwillingness to use oral contraceptives
✕. Other life-threatening medical conditions
✕. Anticipated alcohol or barbiturate use during the study period